PharmaEssentia Corp., a global biopharmaceutical company headquartered in Taiwan, has entered into a license agreement with Wuxi Biologics Ireland Ltd. to obtain the global exclusive rights to develop, manufacture and commercialize a myeloid immune checkpoint antibody candidate. PharmaEssentia will take over responsibility for the subsequent preclinical and clinical development efforts. As part of the agreement, PharmaEssentia will pay license fees to WuXi Biologics, including an upfront paym...